Recruiting × Primary Myelofibrosis × Other hematologic neoplasm × Clear all ACCELERATE
Phase 2 Recruiting
358 enrolled
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Phase 2 Recruiting
25 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
Recruiting
5,000 enrolled
SICP RCT
Phase NA Recruiting
207 enrolled
Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)
Phase 1/2 Recruiting
66 enrolled
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Phase 1 Recruiting
18 enrolled
Two Step Haplo With Radiation Conditioning
Phase 2 Recruiting
63 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 Recruiting
46 enrolled
A Study of GLB-001 in Patients With Myeloid Malignancies
Phase 1 Recruiting
108 enrolled
EpiC
Recruiting
120 enrolled
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Recruiting
Allo HSCT Using RIC and PTCy for Hematological Diseases
Phase 2 Recruiting
56 enrolled
Registry of Older Patients With Cancer
Recruiting
3,000 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)
Phase 1 Recruiting
44 enrolled
UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy
Phase 1 Recruiting
50 enrolled
Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
75 enrolled
Myeloproliferative Neoplasms (MPNs) Patient Registry
Recruiting
5,000 enrolled
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Phase 1 Recruiting
24 enrolled
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1 Recruiting
100 enrolled